Physiomics PLC Results Presentation and DoseMeRx Update (5994N)
30 Septiembre 2021 - 8:59AM
UK Regulatory
TIDMPYC
RNS Number : 5994N
Physiomics PLC
30 September 2021
30 September 2021
Physiomics plc
("Physiomics") or ("the Company")
Presentation of results for the year ended 30 June 2021 and
update on collaboration with TabulaRasa Healthcare's DoseMeRx
subsidiary
Physiomics plc (AIM: PYC), the consultancy using mathematical
models to support the development of drug treatment regimens and
personalised medicine solutions today made a presentation regarding
its final results for the year ended 30 June 2021, using the
Investor Meet Company platform. The slide deck used in the
presentation will be posted on the Company's website at
https://www.physiomics.co.uk/resources/ and a recording of the
presentation, together with the subsequent Q&A, will be made
available on the Investor Meet Company platform and can be accessed
by registering or logging on at
https://www.investormeetcompany.com/physiomics-plc/register-investor
.
During the presentation, Dr Jim Millen, CEO, noted that the
integration of the Company's personalised dosing software tool into
TabulaRasa Healthcare's subsidiary DoseMeRx's existing platform had
been recently completed and that a period of user testing would
take place over the next few months. Further announcements relating
to this collaboration will be made when appropriate. This news
comes shortly after the Company's announcement on 21 September 2021
of the recruitment of the first patient into its PARTNER study
which is being run by Portsmouth Hospitals University NHS Trust and
which is expected to generate further data for the validation and
development of the Company's personalised dosing software
tools.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFVVASIIVIL
(END) Dow Jones Newswires
September 30, 2021 09:59 ET (13:59 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024